fbpx Yourgene Health plc - Home
Infectious Disease
Clarigene RUO
Clarigene CE-IVD
Clarigene SARS-CoV-2 CE-IVD
Clarigene™ Feature Notes
NIPT
IONA® Nx
For Clinical Laboratories
Overview
Workflow
Clinical Performance
Benefits of the IONA® Nx NIPT Workflow
Instruments
IONA® Software
Atlas Workflow Manager
MyNIPT®
Technical Support
Quality and Regulatory
Choose IONA® Nx NIPT Workflow
Post-Market Surveillance
the IONA® test
For Clinical Laboratories
Overview
Technology
CE-IVD
Clinical Performance
Results
MyNIPT®
Application Support
FAQs
Choose IONA®
Laboratory Customer Login
For Pregnant Women
For Healthcare Professionals
Overview
Background
Clinical Performance
Results
MyNIPT®
Who can have the IONA® Test
FAQs
Responsible Screening
Choose IONA®
Resources
Contact Us
Sage™ Prenatal Screen
For Clinical Laboratories
Overview
Technology
Clinical Performance
Results
Choose Sage™
Sage QS 32plex
For Pregnant Women
Advantages of the Sage™ prenatal screen
Overview
Who can have the Sage™ test
Results
For Healthcare Professionals
Overview
Background
Who can have the Sage™ test
Clinical Performance
Results
Clinical Performance
Results
Contact Us
Reproductive Health
Cystic Fibrosis
Cystic Fibrosis Analysis
Choose CF-EU2
Male Infertility
Pregnancy Loss
Rapid Aneuploidy Analysis
QST*R Range
QST*R Feature Notes
Thrombosis Risk Panel
Precision Medicine
Elucigene DPYD
DPYD Overview
DPYD Testing Workflow
Clinical Performance
Choose Elucigene DPYD
Yourgene Flex™
DNA Size Selection / Enrichment
Ranger Technology
LightBench®
Overview
Get to the DNA you care about in NIPT
Get to the DNA you care about in Liquid Biopsy
NGS QC
LightBench® Feature Notes
Yourgene® QS250
Yourgene® SP150

The Elucigene TRP F Plus
4 high risk mutations
Reliable and accurate detection
Simple, easy to use protocol

CE-IVD

Venous thromboembolisms (VTE) occurs in 1-2 individuals per 1000 and there are approximately 10 million cases worldwide. There are between 100,000 and 300,000 VTE related deaths in the US, and 544,000 in Europe each year, which has resulted in a major health economic burden. There are many factors that increase the risk of thrombophilia such as surgery, pregnancy, the use of oral contraceptives and prolonged immobilisation (economy class syndrome).

Genetic factors also contribute to an individual’s risk of VTE. Factor V Leiden is the most common inherited form of thrombophilia, occurring in 3.8% of the general US and European population in a heterozygous state. Heterozygous individuals are 7 fold more likely to develop a VTE, while homozygous individuals have an 80 fold increased risk Prothrombin thrombophilia is the second most common form and occurs in approximately 1 in 50 people in the Caucasian US and European population Mutations in MTHFR are associated with elevated homocysteine levels, an increased risk of blood clots, pregnancy loss or neural tube defects in offspring.

The Elucigene Thrombophilia Range includes:

  • TRP F plus : Factor V Leiden, Factor II, MTHR (677 C>T/1298 A>)

This kit offers detection of the four most relevant mutations implicated in an increased risk of developing venous thromboembolism.

Benefits of the Elucigene Thrombophilia Range

  • Simple to use
  • Reagents ready to use in a single multiplexed tube – just add DNA
  • Minimal hands on time
  • Low failure rates
  • Rapid turnaround time
  • Easy to interpret
  • Optimally balanced primers
  • Test distinguishes between heterozygous and homozygous individuals
  • Assay validated on multiple thermal cyclers and ABI genetic analysers
 

Ordering Information

Kit NameDescriptionPlatformCatalogue Code

TRP-Fplus

Detection of the 4 most common mutations associated with Thrombophilia.

Genetic Analyser

THF04B2